Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.

Eligibility

Inclusion Criteria:

* Age ≥18
* Untreated clinical stage I NSCLC amenable to upfront surgery
* Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery
* ECOG Performance Status of ≤2 Of note, the E-nose is a completely noninvasive technology (only breath samples are collected). Therefore, this intervention would have no effects on a developing human fetus. There are therefore no requirements for the study population related to contraception or pregnancy testing.

Conditions3

Locations7 sites

Browse More Trials